Paper Details

  1. Home
  2. Paper Details

Anakinra for severe forms of COVID-19: a cohort study.

Author: BeaussierHélène, BézieYvonnick, ChatellierGilles, DauriatGaëlle, EmmerichJoseph, HayemGilles, HuetThomas, JouveshommeStéphane, LaplancheSophie, LazarethIsabelle, Le BerreAlice, Le PavecJérôme, MouradJean-Jacques, NaccacheJean-Marc, SaccoEmmanuelle, SalmeronSergio, VoisinOlivier

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to assess the off-label use of anakinra, an IL-1 receptor antagonist, in patients with severe COVID-19 and symptoms of worsening respiratory function.
Paper Details　
Original Abstract of the Article :
Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome cor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259909/

データ提供：米国国立医学図書館（NLM）

Anakinra: A Potential Treatment for Severe COVID-19?

The ongoing battle against COVID-19 is a relentless fight for survival. This study examines the potential of anakinra, a recombinant IL-1 receptor antagonist, as a treatment for severe forms of COVID-19. The authors investigated the use of anakinra in hospitalized patients experiencing severe respiratory distress, a common complication of the disease. Like a seasoned explorer traversing the unforgiving desert, the study seeks to uncover new pathways for treating this formidable foe.

Anakinra: A Potential Oasis in the COVID-19 Desert?

The research suggests that anakinra may hold promise as a treatment for severe COVID-19. It may help to combat the hyperinflammatory state that can lead to acute respiratory distress.

Fighting Inflammation: A Key to COVID-19 Recovery?

Anakinra's potential for treating severe COVID-19 is encouraging. It highlights the importance of addressing the inflammatory response that can be a major factor in the severity of the disease.

Dr.Camel's Conclusion

This research sheds light on a potential therapeutic avenue for severe COVID-19. Anakinra's ability to combat inflammation may be a significant asset in the fight against this complex and challenging disease.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-04-16
Further Info :

Pubmed ID

32835245

DOI: Digital Object Identifier

PMC7259909

Related Literature

Article Analysis
・Side Effects of anakinra
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.